-

11:40:22 PM

BMEA Stock News

BMEA - Biomea Fusion Inc

09/28/23 8:30 AM

Nasdaq : BMEA

clinical trialhigh shortlow float

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with dosing durations up to 12 weeks in type 2 diabetes patients The expansion portion will consist of approximately 300 patients and will

RHEA-AI

neutral

08/31/23 8:30 AM

Nasdaq : BMEA

managementhigh shortlow float

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes Steve Morris, M.D., will transition to the role of Chief Development Officer, continuing to lead clinical

RHEA-AI

positive

07/31/23 4:01 PM

Nasdaq : BMEA

earningshigh shortlow float

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

Reported additional positive clinical data at ADA 83 rd Scientific Sessions from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study (COVALENT-111) evaluating BMF-219 as a novel, potentially disease-modifying treatment candidate for patients with type 2 diabetes New

RHEA-AI

neutral

07/24/23 9:00 AM

Nasdaq : BMEA

high shortlow float

BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4 Dose Level 4 exposure correlates with initial activity seen in BMF-219’s pre-clinical studies Safety profile of

RHEA-AI

neutral

06/23/23 9:54 PM

Nasdaq : BMEA

clinical trialhigh shortlow float

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT), supporting improved beta cell function for these patients Observations of durable and

RHEA-AI

neutral

06/20/23 4:30 PM

Nasdaq : BMEA

conferencesclinical trialhigh shortlow float

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

New clinical data from COVALENT-111 will be unveiled during a late-breaking poster presentation at ADA’s Scientific Sessions BMF-219, an orally delivered novel covalent menin inhibitor, is designed to regenerate, preserve, and reactivate healthy, insulin-producing beta cells Biomea to hold

RHEA-AI

negative

05/02/23 4:01 PM

Nasdaq : BMEA

high shortlow float

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes

RHEA-AI

neutral

05/01/23 8:30 AM

Nasdaq : BMEA

high shortlow float

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

BMF-500, a novel 3 rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the clinic. Phase I study (COVALENT-103) of BMF-500 will examine its safety and efficacy in patients

RHEA-AI

neutral

04/19/23 8:30 AM

Nasdaq : BMEA

conferenceshigh shortlow float

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

Biomea Fusion, Inc. (“Biomea”) (Nasdaq:

RHEA-AI

neutral

04/13/23 4:30 PM

Nasdaq : BMEA

conferenceshigh shortlow float

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor. BMF-219 showed greater potency and ability to achieve >98% growth inhibition in these CLL patient

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

BMEA Data

IndustryResearch and Development in Biotechnology
Websitebiomeafusion.com
Security nameBiomea Fusion Inc
SectorProfessional, Scientific, and Technical Services

About Biomea Fusion Inc

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro